Share ownership IXICO plc

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:19 2026-06-12 EDT			5-day change	1st Jan Change
8.650 ^GBX	0.00%		0.00%	-26.38%

06-08	Ixico plc Announces Appointments on Scientific Advisory Board	CI
06-08	Ixico Has Enters into A Research Collaboration with the Paris Brain Institute	CI

Share class: IXICO plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	218,047,596	194,502,149 ( 89.2 %)	0	89.2 %

Major shareholders: IXICO plc

Name	Stocks	%	Valuation
Canaccord Genuity Asset Management Ltd. 11.24 %	24,500,906	11.24 %	3 M p
Unicorn Asset Management Ltd. 9.969 %	21,737,555	9.969 %	3 M p
Gresham House Asset Management Ltd. 7.393 %	16,120,584	7.393 %	2 M p
BGF Investment Management Ltd. 5.91 %	12,887,000	5.91 %	2 M p
Octopus Investments Ltd. 4.541 %	9,902,257	4.541 %	1 M p
Rathbones Investment Management Ltd. 4.156 %	9,063,000	4.156 %	1 M p
Maven Capital Partners UK LLP 3.706 %	8,081,651	3.706 %	942 321 p
Canaccord Genuity Wealth Ltd. 3.361 %	7,328,224	3.361 %	854 471 p
Riverrock Capital Ltd. (United Kingdom) 1.769 %	3,857,566	1.769 %	449 792 p
Hargreaves Lansdown Asset Management Ltd. 1.322 %	2,883,000	1.322 %	336 158 p
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	54.71%
Individuals	0.38%
Others	0.08%
Unknown	44.83%

Based on 1000 largest holdings

Geographical origin of shareholders

United Kingdom	54.63%
Individuals	0.38%
Luxembourg	0.08%
United States	0.07%
Switzerland	0.01%

Based on 1000 largest holdings

IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.

Employees

Sector

Biotechnology & Medical Research

More about the company